Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals have been moderately successful, with minimal evidence for glucagonomas or metastatic spread. The renin gene, although classically associated with expression in the kidney, is also expressed in many other extrarenal tissues including the pancreas. To induce tumorigenesis within renin-specific tissues, floxed alleles of p53 and Rb were selectively abrogated using Cre-recombinase driven by the renin promoter. The primary neoplasm generated is a highly metastatic islet cell carcinoma of the pancreas. Lineage tracing identifies descendants of renin-expressing cells as pancreatic alpha cells despite a lack of active renin expression in the mature pancreas. Both primary and metastatic tumors express high levels of glucagon; furthermore, an increased level of glucagon is found in the serum, identifying the pancreatic cancer as a functional glucagonoma. This new model is highly penetrant and exhibits robust frequency of metastases to the lymph nodes and the liver, mimicking human disease, and provides a useful platform for better understanding pancreatic endocrine differentiation and development, as well as islet cell carcinogenesis. The use of fluorescent reporters for lineage tracing of the cells contributing to disease initiation and progression provides an unique opportunity to dissect the timeline of disease, examining mechanisms of the metastatic process, as well as recovering primary and metastatic cells for identifying cooperating mutations that are necessary for progression of disease.
INTRODUCTION
Classically, the aspartyl protease renin is recognized for its role in the regulation of blood volume and electrolyte balance as the rate-limiting step in the renin angiotensin system (RAS) cascade through its synthesis and release at the juxtaglomerular cell of the kidney. The RAS has more recently been shown to be critical for normal mammalian renal development with transient expression of renin marking the developing renal vasculature. [1] [2] [3] However, renin expression is not limited to the developing kidney; it is also found in many extrarenal organs 4 including the pancreas, reflecting its potential role as a regulatory system in diverse tissue environments. [5] [6] [7] Although there are extensive publications describing renin and RAS functions in the pancreas, conflicting observations have made it difficult to identify the cellular source of renin expression. [7] [8] [9] [10] [11] [12] [13] [14] [15] For example, multiple lines of evidence have supported renin expression in the rat pancreas, 7 and (pro)renin has been localized to both endothelial cells of pancreatic vasculature as well as beta cells of the human pancreas islets. 8 More recently, highly intriguing in vitro studies have detected renin and its substrate, angiotensinogen, in early-stage differentiating islet cells but not in undifferentiated progenitor cells. 6 There is a large body of data from many groups describing the relation and origin of different lineages of endocrine islet cells of the pancreas. Current understanding suggests that the multiplicity of primary endocrine cell types all differentiate independently from Pdx1-positive progenitor cells that give rise to unipotent precursor cells transiently expressing the Neurogenin3 transcription factor. [16] [17] [18] [19] The specificity appears to be conferred by a shifting window of competency on the part of the pancreatic progenitor cells, whereby they form different endocrine cell types at different developmental stages. 20 Glucagon-expressing cells are the earliest islet cell type to appear during endocrine pancreatic morphogenesis, and the competence for progenitor cells to differentiate into this cell type appears at about 9-10 days in mouse pancreatic rudiment, whereas the competence to make ontogenetically related insulin and pancreatic polypeptide lineage appears between 10.5 and 12.5 days. In the mature islet, the mantle region is the site occupied by glucagon-and somatostatinexpressing cells, 21 whereas the core of the mature islet in mice is predominantly occupied by the insulin-expressing beta cells. 20 Various endocrine cell types can give rise to pancreatic neuroendocrine tumors (PanNETs), which are characterized as functional or non-functional based on the association with syndromes reflecting overproduction of cognate hormones. 22 In humans, glucagonomas are observed to arise at a considerably lesser frequency than insulinomas. 23 They appear to occur primarily sporadically but are infrequently found in association with the Multiple Endocrine Neoplasia (Men1) and von HippelLindau syndromes, in which they can be multicentric. 22 Whereas 1 the tumors are generally slow-growing, 75-80% of glucagonomas tend to be malignant at discovery with 450% exhibiting metastasis. The primary metastatic sites are the regional lymph nodes and the liver. 22 Whereas mutation of p53 is observed in human PanNETs, mutation rates for Rb, per se, appear to be very low. 24, 25 In general, 80% of cancers do not have mutations in the Rb protein but have genetic alterations in other key components of the Rb regulatory pathway. 26 Recent studies strongly support a more wide extant of involvement of the p53 and Rb pathways in PanNETs that is mediated through copy number alteration of negative regulators of these tumor suppressors. In particular, a high fraction of tumors exhibit amplification of the p53-negative regulators MDM2, 4 and WIP1, as well as CDK4, which negatively regulates Rb. 24, 25 High expression of Cdk4, both through increased copy number and activation of the mTOR pathway, has been shown to be coincident with Rb phosphorylation, leading to inactivation in PanNETs. 25 Furthermore, hypermethylation of p16
Ink4a , a Cdk inhibitor, has also been identified in PanNETs. 27 Therefore, whereas Rb itself may not be mutated, it is clear that both the p53 and Rb pathways are compromised at high frequency in the human disease.
Efforts to model PanNETs in animals have been variously successful. Genetic deficiencies for p53 and Rb cooperatively result in the development of endocrine tumors reminiscent of MEN1 cancer predisposition, with the tumor spectrum encompassing numerous tissues but with minimal evidence for glucagonomas specifically, or metastasis. 28, 29 Variant targetings to generate general Men1 deficiency have given variable levels of mimicry of the human disease, predominantly insulinomas with low levels of metastases observed. [30] [31] [32] [33] [34] [35] [36] [37] [38] The RIP-Tag model of Hanahan in which robust and rapid islet cell tumorigenesis is induced has been a highly valuable productive model for studying the tumor progression process. 39 It is limited, however, to development of insulinomas, and metastasis is relatively infrequent in most genetic backgrounds. A parallel construct in which the glucagon promoter was used to drive SV40 Tag has been reported. It exhibited relatively low penetrance, with most animals exhibiting unifocal dysplastic islets with variable functional character and minimal evidence for progression or metastasis. 40 In this paper, we characterize a highly metastatic islet cell carcinoma of the pancreas that results from using a renin-driven cre-recombinase transgene to delete p53 and Rb in reninexpressing cells of the developing mouse. The cancer model developed can be further described as a glucagonoma with metastatic progression to the liver and the lymph node, which mimics the metastatic spread observed clinically in human disease. With insufficient mouse models currently available, this metastatic PanNET model represents an unprecedented tool for studying the cooperating mutations responsible for the development of glucagonomas including progression to metastatic disease.
RESULTS
Renin-specific deletion of p53 and Rb tumor-suppressor genes leads to pancreatic neuroendocrine metastatic disease In an attempt to phenocopy our earlier Ren-SV40Tag studies, which give rise to kidney and subcutaneous tumors at B3-4 months, 41, 42 we utilized a BAC-based RenCre transgenic line that we developed to selectively delete the floxed tumor-suppressor genes p53 and Rb. The RenCre x floxed p53/Rb model gives rise to subcutaneous tumors, albeit infrequently, at B3-4 months of age. However, the primary pathology and lethality of this cross results from the development and metastasis of PanNETs (Figures 1a and b) . At low power, the nodular and highly vascularized nature of the neuroendocrine tumor can be observed ( Figure 1a) ; at higher magnification, the organoid and trabecular growth pattern as well as the stippled chromatin of the primary pancreatic tumor are consistent with pathology characteristic of neuroendocrine disease (Figure 1b) . Furthermore, upon performing necropsies of animals from the RenCre Â floxed p53/Rb cross, metastatic involvement of the liver and the lymph node was observed (Figures 1d, e, g and h) . Similar to the primary tumor, the liver metastases shared the nodular and highly vascularized phenotype (Figure 1d ( Figure 1d ) that is congruent with the metastatic proliferation identified in human disease. The lymph node located adjacent to the pancreas is almost entirely replaced by metastatic neuroendocrine tumor, with only a localized area in the lower left corner containing lymphocytes in the lymph node (Figures 1g and h ).
To further confirm the tumor model as being pancreatic neuroendocrine in origin, immunohistochemical stains for the neuroendocrine tumor markers, synaptophysin and chromogranin A were performed ( Figure 2 ). As seen in this figure, both the primary pancreatic tumor as well as the liver metastases strongly stain for these neuroendocrine markers (brown staining), which is consistent with a primary PanNET that forms multiple metastases in the liver.
To further characterize the lethal phenotype of the PanNET model, 10 animals containing the RenCre transgene and the floxed p53/Rb alleles as well as a negative control group of 10 animals, in which RenCre was not present in the genetic background, were monitored until the animals succumbed or were killed because of the burden of disease. As presented in Figure 3a , the 10 RenCre-positive animals, which expressed the necessary Cre-recombinase to delete p53 and Rb, were euthanized because of morbidity or they died by 29 weeks of age, during which the RenCre-negative littermates exhibited a normal murine lifespan. At necropsy, all RenCre-positive animals exhibited a heavy primary tumor burden and evidence of liver metastases.
Continual monitoring of the RenCre Â floxed p53/Rb animals, as they become ill, has led to several observations in their appearance including scruffy, oily skin/fur and weight loss. When measuring the weight of end-stage RenCre Â floxed p53/Rb animals (17.7±2.16 g) and their RenCre-negative (healthy) littermates (26.2±3.06 g), there is a clear reduction in the mass of the sick animals ( Figure 3b ). This is a 32% reduction in body weight in the sick animals when compared with healthy age-matched littermates, a symptom also found in human pancreatic disease.
Minor frequency of secondary tumor types in the RenCre Â floxed p53/Rb model Although the primary mortality of the RenCre Â floxed p53/Rb animals is from metastatic pancreatic neuroendocrine disease with lethal onset beginning at B22 weeks of age, rare instances of subcutaneous tumors have arisen in the colony leading to the need to euthanize the animals because of tumor burden at B12-16 weeks of age. Furthermore, even more rare instances of mice dying as early as 8 weeks old from yet undetermined causes have also been observed. A detailed cataloging of the RenCre Â floxed p53/Rb mouse colony over 1 year has identified 14 of 120 (B12%) RenCre Â floxed p53/Rb animals that had to be euthanized because of subcutaneous tumor burden or died of unknown causes prior to becoming morbid from pancreatic disease. As seen in Figure 4 , the primary pancreatic tumors and liver metastases are nodular and highly vascularized consistent with neuroendocrine disease; however, the subcutaneous tumors have a more solid growth pattern, although at higher power vessels and extravagated red blood cells can be seen (right panel). The subcutaneous tumor is negative for synaptophysin and chromogranin A and positive for the vascular marker CD31 (data not shown). Therefore, the subcutaneous tumor represents a different primary tumor, consistent with a high-grade vascular sarcoma.
Pancreatic tumors and liver metastasis express high levels of glucagon The pancreases of the animals containing primary tumors were compared with normal pancreas using quantitative PCR (qPCR). As is evident in Figure 5 (Supplementary Table 1 As the primary tumors of the pancreas as well as the metastatic lesions of the liver predominately express the alpha cell marker glucagon, serum levels of circulating glucagon were analyzed at four different time points during the progression of disease ( Figure 6 ). Six RenCre Â floxed p53/Rb animals and 3 Cre À littermates were euthanized at each of the four time points, and their serum was analyzed for circulating glucagon levels. As shown in Figure 6 , the 2-month Cre þ animals did not show an increase in baseline glucagon levels when compared with negative littermates. However, the 4-, 5-and 6-month time points showed a dramatic increase in the circulating glucagon levels. As the primary and metastatic sites of this pancreatic disease not only express glucagon but also secrete glucagon into the blood, this PanNET model can be classified as a glucagonoma.
Progression and metastatic potential of PanNET model Analyzing primary pancreatic tumors collected from different animals at three time points (4, 5 and 6 months) clearly shows substantial growth in the pancreatic tumor from month to month (Figure 7) . At 4 months, the tumor forms two relatively small nodules located in the center of the pancreas. The tumors are B1/3 of the pancreas in this image (Figure 7a ). At 5 months, the tumor nodules have more than doubled in size, taking up almost the entire microscopic field (Figure 7b) . By 6 months, the PanNET cannot fit entirely in the microscopic field and has to be moved off center to get some normal pancreas into the image, thus showing that it is a primary pancreatic tumor (Figure 7c ). High-power ( Â 100) images show that the tumor's morphology and grade do not differ between 4, 5 and 6 months (Figures 7d  and e) . Thus, changes in progression seen are explained by the increased growth and size of the tumor over time.
To further characterize the progression and metastatic potential of the newly developed pancreatic tumor model, 10 RenCre Â floxed p53/Rb mice were euthanized at each of the three time points (4, 5 and 6 months of age), and a full necropsy was carried out by RADIL veterinary services including glucagon immunohistochemistry (IHC) on pancreas and liver tissues. As detailed in Table 1 , all 30 mice (10 from each age group) had primary pancreatic tumors that stained for glucagon. One metastatic lesion (10%) was found in the 4-month-old animals, whereas at the 5 and 6 month time points 30% and 40% of the animals had identifiable glucagon-positive metastasis to the liver, respectively. All primary tumors of the pancreas and metastasis identified in the liver stained with glucagon, suggesting that the alpha cell may be the only source of this metastatic disease. A high level of variation in the severity of the metastatic phenotype was observed in the 6-month-old mice (Figure 8 ). One animal within the 6-month time point contained several central veins of the liver filled with large neoplastic glucagon-staining cells without any detectable metastatic nodules (data not shown). Furthermore, as seen in Figure 8 , the level of metastatic spread identified in different animals varies from a few small aggregates of glucagon-staining cells in the sinusoids (upper panels) to larger clusters of glucagon-expressing cells (middle panels) to multiple large metastatic nodules. Within the most advanced liver metastases the glucagon staining is not evident within every metastatic lesion (Figure 8, lower panel) . Although some of the large advanced foci lack glucagon expression, they are composed of neoplastic cells similar to those found in the primary pancreatic nodules (previous IHC) and may represent a non-functional neuroendocrine tumor, in which no or insignificant amounts of excess hormone are produced by the
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Subcutaneous Tumor Liver Figure 1) . The cells of the pancreas that show evidence of having lineally expressed renin are primarily found in the mantle region, with few cells evident in the core region ( Figure 10 ). Using immunohistochemistry, glucagon-and somatostatin-expressing cells located in the mantle region were distributed in a similar pattern as GFP; however, only a minimal number of GFP-expressing cells appear to localize within the insulin-expressing core domain (Figure 10 ). Using the RenCre Â Confetti model, where the Confetti reporter will randomly label each renin-expressing cell with one of four fluorescent reporters allowing for independent lineage tracing of individual cells, further confirmed the distinct labeling of the islet cells of the pancreas (Figure 9b) . Moreover, because of the fact that all the islets are not of the same color, nor are individual islets monochromatic, the expression of renin in pancreatic development occurs after, or is coincident with, the commitment of a pool of cells destined for the alpha cell lineage and that each islet is made up of multiple progenitors.
To trace the lineal descendant of the renin-expressing cell within the PanNET model, the renin-expressing cells were tagged within the RenCre/p53/Rb cross by introducing the Zsgreen reporter into the RenCre/p53/Rb background. This complex genetic cross allows for the cells that have lineally expressed renin to be tagged with GFP even after renin expression is turned off. The primary tumors identified in the pancreas (Figure 9c descendants of renin-expressing cells. Future studies will utilize the confetti reporter crossed into the RenCre/p53/Rb cross in an effort to connect metastases with primary pancreatic tumors responsible for their origin.
DISCUSSION
Conditional deletion of p53 and Rb, specifically within the reninexpressing cells of the developing mouse, has led to the serendipitous development of a highly robust model for metastatic glucagonoma, which faithfully mimics the key features of corresponding human disease including a high metastatic potential to clinically relevant sites such as the liver and regional lymph nodes. Initially, in an effort to phenocopy our earlier RenSV40TAg studies, which were observed to give rise primarily to kidney and subcutaneous tumors at B3-4 months, 41, 42 we generated a genetic cross with RenCre and floxed alleles for both p53 and Rb, which are the primary targets of SV40 T-antigen. This genetic cross allows for the renin-specific deletion of the p53 and Rb alleles within renin-expressing cells of the developing mouse. Although the RenCre/p53/Rb does give rise to infrequent subcutaneous tumors at B3-4 months, the primary pathology and cause of morbidity in this model are metastatic islet cell carcinoma of the pancreas. Interestingly, incidental pancreatic tumors have been noted in the Ren-SV40Tag animals at autopsy (data not shown), although morbidity of these animals was due to kidney and subcutaneous tumor burden.
Whereas mutation of p53 is observed in human PanNETs, the mutation rates for Rb appear to be very low. 24, 25 However, recent studies strongly support a greater involvement of these pathways in PanNETs, which are mediated through copy number alteration of negative regulators of these tumor suppressors. In particular, a high fraction of tumors exhibit amplification of the p53-negative regulators MDM2, 4 and WIP1, and CDK4, which is also known to negatively regulate Rb. 24, 25 Specifically, increased expression of CDK4 because of elevations in copy number and through the activation of the mTOR pathway via PTEN and TSC2 mutations leads to phosphorylation of Rb in a majority of human PanNETs. 25 Rb has also been shown to be inactivated in PanNETs through hypermethylation of the CDK inhibitor p16
INK4a
. 27 Mouse models have further validated the clinical observation that the p53 and Rb pathways are involved in the tumorigenic process in PanNETs. Included in these studies are the development of insulinomas found in the RIP1-Tag2 mouse, which inactivates p53 and Rb. 43 Other studies using double knockout mice for the Cdk inhibitors p18
INK4c and p27 KIP1 have been shown to develop islet cell hyperplasia. 44 Furthermore, mice containing a mutant Cdk4 (R24C) allele, which cannot be downregulated by p16 INK4a , produce a large number of tumors including PanNETs. 45, 46 Therefore, although Rb itself may not be mutated, it is clear that both the p53 and Rb pathways are compromised at high frequency in PanNETs.
Renin is not expressed with abundance in mature pancreas; however, as previously discussed several independent transgenic lines report evidence for renin expression in lineal precursors of mature glucagon-expressing islet cells. Notably, in support of this interpretation, some highly intriguing results have very recently been reported by Leung et al. 6 in their studies of human pancreatic progenitor cells and their differentiation to islet cells during in vitro culture. They observed highly regulated expression of various components of the rRAS throughout the progenitor cell differentiation process. In particular, renin and the precursor substrate, angiotensinogen, were detected selectively in earlystage differentiating islet cells but not in undifferentiated progenitor cells. These highly provocative results are fully consistent with our observations, suggesting transient renin expression during the differentiation process.
We also performed independent lineage-tracing analysis of individual islet cells to determine the nature of the progenitor cell differentiation process of the endocrine pancreas. Using the Confetti mice crossed to the RenCre mice (wild-type p53 and Rb) identified a distinct labeling pattern of the islet cells of the pancreas (Figure 9b monochromatic, we can infer that the expression of renin in pancreatic development occurs after, or is coincident with, commitment of a pool of cells destined for the a-cell lineage and that each islet is composed of descendants of multiple progenitors. Such inferences are consistent with recent findings that indicate there is no expansion of the committed a-cell population arising from the unipotent progenitor cells. 17 We believe our data can be coherently unified by a central hypothesis proposing that renin is transiently expressed during early glucagon lineage differentiation. We further argue that the RenCre-driven loss of p53 and Rb in these cells at this early stage predisposes them to stochastic acquisition of further genetic and epigenetic damage resulting in carcinogenesis in those rare cells in which the correct cooperating mutations occur. We propose that a specific genomic insult is required for the cells to attain a metastatic phenotype. Whether the high levels of metastasis observed reflects the time-dependent occurrence of additional mutational hits or a different spectrum of cooperating 'initial' hits will ultimately need to be examined further. This way includes the discovery of novel genes responsible for progression of disease or the identification of already known factors in human pancreatic neuroendocrine cancer including Men1 and von Hippel-Lindau, as well as components of the p53 and Rb pathways.
As previously mentioned, efforts to model PanNETs in animals have been moderately successful, with minimal evidence for glucagonomas or metastatic spread. 28, 29 In contrast, the model we have created is unique for the glucagonoma subtype of PanNET, highly penetrant and exhibits robust frequency of metastases to the lymph nodes and the liver, which are also the major sites of metastatic disease in man. This model will provide a useful platform to better understand pancreatic neuroendocrine differentiation and development, as well as islet cell carcinogenesis. Furthermore, the ability to use fluorescent reporters for lineage tracing of the cells contributing to disease initiation and progression provides a unique opportunity to dissect the timeline of disease pathology. Given the robust metastatic spread, this model also holds promise as a platform for examining mechanisms and features of the metastatic process generally, as well as devising and optimizing therapeutic intervention strategies. Additionally, the increased palette of colors conferred by the multiple flourephores of the Confetti model affords an enhanced ability to address fundamental issues such as assessing hyperplasia within pretumorigenic islets, determining clonality of primary tumor foci and correlating metastases with their primary tumor of origin. This model will allow for dissecting clonal evolution of metastases-will, indeed, H&E Glucagon Ab Figure 8 . Variation in severity of metastatic disease in RenCre/p53/Rb tumor model. Liver sections from 6-month-old end-stage RenCre/p53/Rb mice stained with glucagon Ab (left panels, black arrows), and H&E stain (right panels) show varying levels of severity of metastasis to the liver.
allow for the dissection of multiple potential routes of acquisition of the metastatic phenotype-in an experimental format that cannot be matched by studying human tumors.
MATERIALS AND METHODS

Construction of RenCre BAC transgenic line
Insertion of the Cre-recombinase downstream of the renin promoter region within the RP23-88k07 BAC was performed as previously described and the transgenic line created is termed RenCre within this manuscript. 47, 48 Multiple expressing RenCre transgenic lines were developed to ensure faithful transgene expression with natural renin expression without positional effects because of insertion within the BAC construct. Validation of faithful reporting of the multiple RenCre transgenic lines was carried out by crossing RenCre to the floxed-stop-floxed-GFP reporter construct, B6.Cg-Gt(ROSA)26Sor tm6(CAG-ZsGreen1)Hze /J (Zsgreen) reporter line. Kidneys from animals positive for both RenCre and Zsgreen were dissected and visualized to confirm accurate GFP reporting of endogenous renin expression (manuscript in submission). Furthermore, to test the recombination efficiency of our RenCre transgenic line, we crossed it with both the Zsgreen reporter as well as an floxed-stop-floxed-RFP reporter, B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (Tomato) simultaneously. By assessing the percent of cells that are both green and red compared with the total cells marked with only a single reporter within the kidney of the mouse containing all three transgenes, we deduce B75% recombination efficiency of the RenCre transgenic line.
Generation of pancreatic tumor model
To generate the metastatic pancreatic tumor model, a RenCre BAC transgenic line was crossed to p53 loxP/loxP Rb loxP/loxP mice. 
Genotyping
Homozygous p53 loxP/loxP Rb loxP/loxP animals were maintained as a homozygous stock. Identification of wild-type, un-recombined floxed allele and recombined floxed allele for both p53 and Rb has been previously described. 51 The RenCre transgenic animals were identified using the primers CreF 5 0 -GAATTGTAATACGACTCACTATAGG-3 0 and CreR-5 0 -ATC GCCATCTTCCAGGCGCACC-3. A 1100-bp Cre fragment is generated using the PCR cycling parameters: 94 1C 5 min initiation, followed by 40 
Pathology assessment
Mice were killed using CO 2 affixiation followed by cervical dislocation according to the guidelines from Roswell Park Cancer Institute's Animal Care and Use Committee. Full necropsies were performed on animals with pancreatic disease. Samples of tissue from multiple organs including pancreas, liver, lung and heart were fixed in 4% paraformaldehyde. Fixed tissues were sent to IDEXX RADIL (Columbia, MO, USA) and processed for paraffin embedment, blocked in wax and cut in 5-mm sections, which were stained with hematoxylin and eosin. Additional sections for immunohistochemistry were probed with an anti-glucagon, anti-synaptophysin, antichromogranin A and anti-CD 31 antibody using standard procedures. Briefly, 5-mm sections were mounted onto ProbeOn Plus microscope slides (Fisher Scientific Inc, Pittsburgh, PA, USA), de-waxed in xylene and rehydrated through graded concentrations of ethanol and finally in water. Sections were treated with 3% hydrogen peroxide (to inactivate endogenous peroxidase activity) and rinsed prior to incubation in blocking buffer with 5% bovine serum albumin for 20 min. Sections were then incubated for 60 min at room temperature with anti-glucagon antibody (1:50 dilution of a rabbit polyclonal antibody; 180064, Invitrogen, Grand Island, NY, USA). Sections were then washed, incubated for 30 min with a horseradish peroxidase-labeled polymer conjugated to anti-rabbit antibodies (EnVision, DAKO, Carpenteria, CA, USA). Bound antibodies were visualized following incubation with 3,3 0 -diaminobenzidine solution (0.05% with 0.015% H 2 O 2 in phosphate-buffered saline; DAKO) for 3-5 min. Sections were counterstained with Mayer's hematoxylin, dehydrated and cover-slipped for microscopic examination.
Immunohistochemical analysis
Tissues for analysis were placed into ice-cold 2% buffered formalin-20% sucrose immediately after collection and kept overnight at 4 1C. These tissues were snap-frozen in optimal cutting temperature (OCT) embedding medium and 5 mm serial sections were collected onto silane-treated slides. Slides were stored at À 20 1C until staining when they were dried at room temperature, and briefly heat-fixed at 55 1C To stain, slides were rehydrated in phosphate-buffered saline and blocked in 5% normal donkey serum and 0.05% Tween 20. Slides were stained using antibody to Glucagon (rabbit polyclonal SKU Ab932, Millepore, Billerica, MA, USA), Somatostatin (rabbit polyclonal SKU NB100-91966, Novus Biologicals, Littleton, CO, USA) or Insulin (guinea pia polycolonal SKU 4011-01F, Millepore) and incubated for 1 h at room temperature. After washing, either donkey anti-rabbit Alexa Fluor 594 (SKU 21207, Molecular Probes, Eugene, OR, USA) or donkey anti-guinea pig DyLight 594 (SKU 706-515-148, Jackson Immuno, West Grove, PA, USA) was applied for 30 min at room temperature. After washing in phosphate-buffered saline, slides were mounted with Fluoroshield with DAPI (SKU F6057, Sigma-Aldrich, St Louis, MO, USA). Slides were viewed on a Nikon Eclipse E600 (Melville, NY, USA) microscope using an X-Cite 120 fluorescent illumination system (ExFO, Quebec, QC, Canada). Images were recorded with an RT SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI, USA).
In situ visualization of GFP
To visualize GFP expression in tissues of RenCre Â Zsgreen genetic crosses, fluorescent stereomicroscopy was performed (model ZX12, Olympus, Center valley, PA, USA) with mercury bulb illumination through an MGFP excitation/emission filter (Olympus). Images were captured with a Spot RT digital camera and software (Diagnostic Instruments) at identical exposures.
In Situ visualization of confetti
Confocal images were acquired with a Zeiss LSM 710 by sequential scanning of individual probes using a Â 20, 0.8 NA objective. A 405-nm diode laser was used for cyan flourescent protein (CFP) excitation (em 465-495), a 488-nm argon laser for green flourescent protein (GFP) (em:499-511), a 514-nm Argon laser for yellow flourescent protein (YFP) (em 520-560), and the 553 nm line from an 'In Tune' Laser for red flourescent protein (RFP) (em 589-652). Excitation and collection settings used for each color of the confetti line have been previously described. 52 RNA isolation and real-time PCR RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). One microgram of RNA was reverse-transcribed in a 100-ml reaction using the high-capacity complementary DNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommendation. SYBR Green qPCR primers were designed using Beacon Design Software (Bio-Rad, Hercules, CA, USA) using the default parameters for qPCR primers. When possible, amplicons were designed to span introns-exon boundaries. The qPCR reaction was carried out in 10 ml volume using 2 Â Bio-Rad iQ SYBR Green Master Mix (Bio-Rad), 1 ul cDNA and 200 ng of primer. The qPCR reactions were performed with a CFX96 (Bio-Rad) using the manufacturer's suggested cycling conditions.
Glucagon serum measurements
Mice were killed using CO 2 affixiation followed by cervical dislocation according to the guidelines from Roswell Park Cancer Institute's Animal Care and Use Committee. Cardiac puncture with a 32-gauge needle and 1-ml syringe was used to extract blood from mouse. Serum was collected using centrifugation, snap-frozen and subsequently stored at À 80 1C. Once all time points and samples were collected, serum was shipped to Ani Lytics Inc (Gaithersburg, MD, USA) where glucagon levels were measured in pg/ml and reported back to Roswell Park Cancer Institute.
